Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
Download PDF
Thromb Haemost 2002; 87(05): 925-926
DOI: 10.1055/s-0037-1613110
DOI: 10.1055/s-0037-1613110
Letters to the Editor
Pulmonary Embolism After Sequential Use of Recombinant Factor VIIa and Activated Prothrombin Complex Concentrate in a Factor VIII Inhibitor Patient
Authors
Further Information
Publication History
Received
25 January 2002
Accepted
30 January 2002
Publication Date:
11 December 2017 (online)
-
References
- 1 Kessler CM. New products for managing inhibitors to coagulation factors: a focus on recombinant factor VIIa concentrate. Curr Opin Hematol 2000; 07: 408-13.
- 2 Ewenstein BM. Continuous infusion of recombinant factor VIIa: continue or not?. Thromb Haemost 2001; 86: 942-4.
- 3 Aledort LM. Adverse reactions related to rVIIa?. Am J Hematol 2001; 67: 213.
- 4 van ’t Veer C, Golden NJ, Mann KG. Inhibition of thrombin generation by the zymogen facto VII: implications for the treatment of hemophilia A by factor VIIa. Blood 2000; 95: 1330-5.
- 5 Monroe DM, Hoffman M, Oliver JA, Roberts HR. A possible mechanism of activated factor VII independent of tissue factor. Blood Coag Fibrinol 1998; 09 Suppl: (Suppl. 01) S15-S20.
- 6 Key NS, Christie B, Henderson N, Nelsestuen GL. Possible therapeutic synergy between recombinant factor VIIa (rFVIIa) and prothrombin complex concentrate (PCC) in the treatment of hemophilia with inhibitors: evaluation of an in vitro test. Blood 2001; 96: 519a.